Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)
Public ClinicalTrials.gov record NCT05291091. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of EDG-5506 on Safety, Biomarkers, Pharmacokinetics, and Functional Measures in Adults and Adolescents With Becker Muscular Dystrophy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A study of sevasemten (EDG-5506) in Becker muscular dystrophy (known as CANYON) and pivotal cohort (known as GRAND CANYON). The EDG-5506-201 CANYON study was expanded to include an additional 120 adult participants in a cohort called GRAND CANYON, that is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of sevasemten in adults with Becker. CANYON and GRAND CANYON are fully enrolled.
Study identification
- NCT ID
- NCT05291091
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 244 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years to 50 Years
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 9, 2022
- Primary completion
- Aug 31, 2026
- Completion
- Aug 31, 2026
- Last update posted
- Jul 30, 2026
2022 – 2026
United States locations
- U.S. sites
- 26
- U.S. states
- 19
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arkansas Children's Hospital | Little Rock | Arkansas | 72202 | — |
| UC San Diego | La Jolla | California | 92037 | — |
| UCLA Medical Center | Los Angeles | California | 90095 | — |
| UC Irvine Medical Center | Orange | California | 92868 | — |
| Stanford Neuroscience Health Center | Palo Alto | California | 94304 | — |
| UC Davis Medical Center | Sacramento | California | 95817 | — |
| UC Denver | Aurora | Colorado | 80045 | — |
| University of Florida | Gainesville | Florida | 32611 | — |
| Rare Disease Research | Atlanta | Georgia | 30329 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Indiana University School of Medicine | Indianapolis | Indiana | 46202 | — |
| University of Iowa | Iowa City | Iowa | 52242 | — |
| University of Kansas Medical Center | Kansas City | Kansas | 66160 | — |
| Kennedy Krieger Institute | Baltimore | Maryland | 21205 | — |
| University of Massachusetts Memorial Medical Center | Worcester | Massachusetts | 01605 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| University of Rochester Medical Center | Rochester | New York | 14642 | — |
| Rare Disease Research, LLC NC | Hillsborough | North Carolina | 27278 | — |
| University of Cincinnati Gardner Neuroscience Institute | Cincinnati | Ohio | 45219 | — |
| Nationwide Children's Hospital | Columbus | Ohio | 43205 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15224 | — |
| National Neuromuscular Research Institute | Austin | Texas | 78759 | — |
| Neurology Rare Disease Center | Denton | Texas | 76208 | — |
| Virginia Commonwealth University Health | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.
Recently updated Becker Muscular Dystrophy trials
Other public records listing Becker Muscular Dystrophy. Sorted by last update posted; newest first. Not a recommendation.
- NCT07674758: Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials Recruiting
- NCT05257473: Defining Endpoints in Becker Muscular Dystrophy Active, not recruiting
- NCT07609394: Duchenne Electronic Health Record Study Recruiting
- NCT02069756: The Duchenne Registry Recruiting
- NCT05019625: Biomarker Development for Muscular Dystrophies Recruiting
- NCT01484678: Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05291091, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 30, 2026 · Synced Aug 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05291091 live on ClinicalTrials.gov.